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Abstract 
Background: To evaluate the immunomodulating and clinical effects of nilotinib, a tyrosine kinase inhibitor, in a 
proof-of-concept study in spondyloarthritis (SpA) assessing the mast cell as potential novel therapeutic target in this 
disease.
Methods: Twenty eight patients with active peripheral (pSpA) and/or axial SpA (axSpA) were included in a rand-
omized, double-blind, placebo-controlled clinical trial (Trial registration: Trialregister.nl NTR2834). Patients were treated 
1:1 with nilotinib or placebo for 12 weeks, followed by an open label extension for another 12 weeks. Paired synovial 
tissue biopsies, serum sampling and assessment of clinical symptoms were performed serially.
Results: In pSpA (n = 13) synovial inflammation appeared to diminish after 12 weeks of nilotinib treatment as 
evidenced by histopathology (decrease in number of infiltrating CD68+ and CD163+ macrophages and mast cells). 
Compared to placebo mRNA expression of c-Kit as mast cell marker (p = 0.037) and of pro-inflammatory cytokines 
such as IL-6 (p = 0.024) were reduced. The reduction of synovial inflammation was paralleled by a decrease in serum 
biomarkers of inflammation such as C-reactive protein (p = 0.024) and calprotectin (p = 0.055). Also clinical param-
eters such as patient’s global assessment of disease activity (p = 0.031) and ankylosing spondylitis disease activity 
score (p = 0.031) showed improvement upon 12 weeks of nilotinib but not placebo treatment. This improvement was 
further augmented at week 24. In contrast to pSpA, neither serum biomarkers of inflammation nor clinical parameters 
improved upon nilotinib treatment in axSpA. During the trial one serious adverse event occurred, which was consid-
ered unrelated to the study drug.
Conclusions: This small proof-of-concept study suggests that nilotinib treatment modulates inflammation and clini-
cal symptoms in pSpA. A similar effect was not seen in axSpA.
Trial registration: trialregister.nl registration code NTR2834 registered 31 March 2011
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Background
The introduction of tumor necrosis factor (TNF) inhibi-
tors has improved the management of spondyloarthri-
tis (SpA) tremendously [1]. However, some patients do 
not respond sufficiently to TNF inhibitors or experience 
side effects. Also, treatment discontinuation leads to 
fast relapse of disease [2, 3], and pathological osteopro-
liferation continues under anti-TNF treatment [4–8]. 
Accordingly, there is still an unmet medical need for new 
therapies.
Immunopathological studies on peripheral SpA (pSpA) 
synovitis recently identified the mast cell as potential 
therapeutic target. Mast cells are key players of the innate 
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cytokines [9, 10]. Besides their well-established role in 
allergies, these cells also play an important role in rheu-
matoid synovitis [9–13]. We recently proposed that mast 
cells might be more important in SpA than in rheuma-
toid arthritis (RA) based on the following: [13] Firstly, 
the infiltration with c-Kit +  mast cells in SpA synovitis 
is markedly higher compared to RA. Secondly, this infil-
tration is already observed in early disease and is not 
affected by effective anti-TNF treatment. Thirdly, mast 
cells are the major interleukin (IL)-17 expressing cells in 
pSpA and the proportion of mast cells expressing IL-17 
is significantly higher in SpA than RA synovitis. Fourthly, 
proof-of-concept studies demonstrated that IL-17A 
blockade effectively down-modulates inflammation and 
clinical symptoms in the ankylosing spondylitis (AS) and 
psoriatic arthritis (PsA) subtypes of SpA [14–16]. Finally, 
sulfasalazine, the only disease-modifying anti-rheumatic 
drug (DMARD) with proven efficacy in pSpA [17], has 
shown to inhibit degranulation and TNF secretion by 
mast cells [18, 19].
Mast cells can be targeted in  vivo by tyrosine kinase 
inhibitors such as imatinib and nilotinib, which are reg-
istered for the treatment of chronic myeloid leukemia 
(CML) [20, 21]. Originally developed to inhibit c-Abl 
on malignant leucocytes, these drugs also appeared to 
inhibit c-Kit, the receptor for stem cell factor, thereby 
inducing apoptosis of mast cells, including synovial 
mast cells [22]. Accordingly, we recently demonstrated 
in ex  vivo biopsy tissue cultures that imatinib strongly 
reduced spontaneous production and secretion of pro-
inflammatory cytokines including IL-6, IL-8 and IL-17 by 
SpA synovium [13]. In line with this data, a small open 
label trial with imatinib in six SpA patients showed a 
decrease in clinical and serum markers of disease activity 
upon 3 months of treatment [23].
The objective of the present study was to evaluate 
mast cells as potential therapeutic target in SpA by con-
ducting a proof-of-concept randomized controlled trial 
with nilotinib. Nilotinib is a second-generation tyros-
ine kinase inhibitor which is more effective in the treat-
ment of CML and has a better safety profile compared to 
imatinib [24, 25]. As the rational for tyrosine kinase inhi-
bition is mainly based on synovial studies, we explored 
the immunomodulating effects on synovial histopathol-
ogy, systemic inflammation, and symptoms of pSpA. 
Additionally, we evaluated clinical efficacy in axial SpA 
(axSpA) in this exploratory study.
Methods
Patients and study design
Twenty-eight patients diagnosed with SpA by their treat-
ing rheumatologist and fulfilling the European Spon-
dyloarthropathy Study Group (ESSG) criteria [26] were 
included in a single centre, double-blind, investigator ini-
tiated clinical trial and randomized (1:1) to receive nilo-
tinib (Tasigna; Novartis Pharmaceuticals) 400  mg twice 
daily or matching placebo capsules (Tiofarma B.V.) for 
12 weeks, followed by an open label extension with nilo-
tinib for another 12  weeks. The Assessment of Spondy-
loarthritis International Society (ASAS) criteria were not 
yet published when this clinical trial was designed, there-
for the ESSG criteria were used in this study. Patients 
were considered to have pSpA when they had an arthri-
tis, to have axSpA when they had inflammatory back 
pain, and combined disease if they had both an arthritis 
and inflammatory back pain. Patients were between 18 
and 65 years old and had active disease despite treatment 
with non-steroidal anti-inflammatory drugs (NSAIDs). 
Active disease was defined as: patient’s and physician’s 
global assessment of disease activity of ≥40  mm, as 
well as ≥1 swollen and ≥1 tender joint in case of pSpA 
(n  =  11), Bath ankylosing spondylitis disease activity 
index (BASDAI) of ≥4 in case of axSpA (n = 15), or both 
in case of combined disease (n = 2). The cohort included 
ten AS, ten PsA, and eight undifferentiated SpA patients. 
Stable doses of NSAIDs, corticosteroids (≤10  mg/day 
prednisone equivalent), methotrexate, sulfasalazine 
and leflunomide were allowed during the trial, but not 
intra-articular corticosteroids. Prior anti-TNF therapy 
(in case the reason for discontinuation was not primary 
failure) was permitted after a washout period (≥4 weeks 
in case of etanercept, ≥8 weeks in case of infliximab and 
≥10  weeks for the other TNF inhibitors). All patients 
gave written informed consent to participate in the study 
as approved by the Ethics Committee of the Academic 
Medical Center/University of Amsterdam (Trialregister.
nl registration code NTR2834). Clinical characteristics at 
baseline are summarized in Table 1.
Synovial immunopathology
Synovial biopsies were obtained by mini-arthroscopy at 
baseline, weeks 12 and 24 in pSpA patients with active 
knee or ankle arthritis (n  =  8) as described previously 
[27, 28]. Samples (6–8 per patient) were either snap-
frozen in Tissue-Tek® O.C.T.™ (Sakura) for histological 
evaluation or immediately stored in liquid nitrogen for 
subsequent RNA extraction and gene expression analysis.
For histopathology, cryostat sections (5  μm) were cut 
and mounted on Star Frost adhesive glass slides (Knittel-
gläser, Braunschweig). Frozen sections were acetone fixed 
and stained with monoclonal antibodies directed towards 
macrophages (CD68; EBM-11, Dako), alternatively acti-
vated macrophages (CD163; 5cFAT, BMA Biomedicals), 
and mast cells (c-Kit; 104D2; BioLegend). After rins-
ing, sections were sequentially incubated with a bioti-
nylated secondary antibody, a streptavidin-horseradish 
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peroxidise link, aminoethylcarbazole substrate as chro-
mogen (all Dako), and hematoxylin as counterstain. 
Parallel sections were incubated with isotype and con-
centration-matched monoclonal antibodies as nega-
tive controls. Samples were stained in a single run to 
minimize technical biases. Stained sections were scored 
semiquantitatively for cellular infiltration by three inde-
pendent observers (NY, ICB and DB) who were blinded 
to the patient’s treatment allocation and treatment dura-
tion, as described previously [29–31].
For gene expression analysis, mRNA was extracted 
using RNA Stat-60 (Tel-Test), then treated with DNase 
I (Invitrogen) and reverse-transcribed using a Rever-
tAid H Minus First Strand complementary DNA Syn-
thesis Kit (Fermentas). The RNA concentration was 
determined with a NanoDrop spectrophotometer. Analy-
sis of mRNA by qPCR was performed using a StepOne-
Plus Real-Time PCR System (Applied Biosystems) using 
GAPDH as housekeeping gene. Predesigned TaqMan 
probe and primer sets for IL-6 (Hs00174131_m1), IL-8 
(Hs00174103_m1), TNF (Hs00174128_m1), IL-17A 
(Hs00174383_m1), IL-17F (Hs00369400_m1), IL-23 
(Hs00372324_m1), c-Kit (Hs00174029_m1), and GAPDH 
(4310884E) were assayed according to the manufacturer’s 
protocol (Applied Biosystems).
Serum biomarkers
Serum analysis included safety measurements (liver 
function, renal function, blood cell counts) as well as 
C-reactive protein (CRP) and erythrocyte sedimentation 
rate (ESR). Serum levels of matrix metalloproteinase-3 
(MMP-3, Biotrak, Amersham Pharmacia Biotech) and 
calprotectin (Hycult Biotech), two potential biomark-
ers of inflammation in SpA [32, 33], were measured by 
enzyme-linked immunosorbent assays (ELISAs) accord-
ing to the manufacturer’s instructions.
Clinical assessments
Clinical assessments consisted of safety evaluation (con-
sisting of the patient’s history, physical examination, 
laboratory tests, urinalysis and electrocardiograms), 
patient’s and physician’s global assessment of disease 
activity on a visual analogue scale, ankylosing spondylitis 
disease activity score (ASDAS) and ASDAS improvement 
criteria [34, 35] in all patients. This was complemented by 
swollen and tender joint count (SJC66 and TJC68) in case 
Table 1 Baseline characteristics of the study population by treatment group
Significance of the comparisons is determined by Mann–Whitney U test for continuous variables and Fisher’s exact test for categorical variables. There were no 
significant differences between the nilotinib and placebo groups
SpA spondyloarthritis; IQR interquartile range; BASDAI bath ankylosing spondylitis disease activity Index; CRP C-reactive protein; ESR erythrocyte sedimentation rate; 
NSAIDs non-steroidal anti-inflammatory drugs; TNF tumor necrosis factor; NA not applicable
Peripheral SpA Axial SpA
Nilotinib (n = 5) Placebo (n = 8) Nilotinib (n = 8) Placebo (n = 9)
Age, median (IQR) years 39.5 (37.4–52.3) 47.1 (31.8–60.4) 38.0 (36.1–42.4) 40.1 (34.5–46.7)
Disease duration, median (IQR) years 4.6 (1.0–9.4) 8.4 (4.4–11.5) 5.8 (1.8–15.3) 4.0 (1.6–12.7)
Number of men/women 3/2 4/4 7/1 6/3
Inflammatory back pain (history/presence), n (%) 0 (0.0) 3 (37.5) 8 (100.0) 9 (100.0)
Peripheral arthritis (history/presence), n (%) 5 (100.0) 8 (100.0) 3 (37.5) 3 (33.3)
Enthesitis (history/presence), n (%) 0 (0.0) 3 (37.5) 3 (37.5) 6 (66.7)
Dactylitis (history/presence), n (%) 1 (20.0) 0 (0.0) 0 (0.0) 0 (0.0)
Patient’s global assessment, median (IQR) mm 52.0 (42.5–64.5) 63.5 (50.8–82.5) 67.0 (49.8–70.8) 70.0 (59.5–86.0)
Physician’s global assessment, median (IQR) mm 46.0 (43.5–64.5) 55.5 (49.0–59.5) 56.5 (47.3–58.0) 55.0 (50.0–60.0)
66 Swollen joint count, median (IQR) 9.0 (3.0–17.5) 3.5 (1.0–8.0) NA NA
68 Tender joint count, median (IQR) 8.0 (0.5–19.5) 9.5 (3.5–11.8) NA NA
BASDAI, median (IQR) NA NA 5.9 (4.2–6.9) 5.4 (4.9–6.8)
CRP, median (IQR) mg/l 9.2 (0.6–29.5) 14.8 (3.0–51.7) 4.8 (3.2–5.4) 6.3 (2.6–15.2)
ESR, median (IQR) mm/h 7.0 (3.5–31.5) 10.5 (5.0–42.3) 8.5 (2.0–12.0) 16.0 (3.5–36.5)
Concomitant NSAIDs, n (%) 4 (80.0) 6 (75.0) 8 (100.0) 9 (100.0)
Concomitant corticosteroids, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Concomitant methotrexate, n (%) 2 (40.0) 4 (50.0) 2 (25.0) 0 (0.0)
Concomitant sulfasalazine, n (%) 2 (40.0) 0 (0.0) 1 (12.5) 0 (0.0)
Previous anti-TNF treatment, n (%) 1 (20.0) 2 (25.0) 2 (25.0) 2 (22.2)
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of pSpA, and BASDAI and BASDAI50 response in case 
of axSpA [36, 37].
Statistical analysis
Data are presented as the median and interquartile range 
(IQR). pSpA and axSpA were analyzed separately as the 
rational for tyrosine kinase inhibition is mainly based on 
synovial studies in pSpA and the assessment in axSpA 
was more exploratory. In case of combined SpA the 
patient’s data were included in both groups. The nilo-
tinib and placebo group were compared to each other 
by Mann–Whitney U tests for continuous variables and 
Fisher’s exact test for categorical variables. Differences 
between various time points were assessed by Wilcoxon 
matched pairs tests by treatment group. For biological 
data (synovial immunopathology and systemic biomark-
ers) the weeks 0–12 data of the original nilotinib group 
were pooled with the weeks 12–24 data of the original 
placebo group (which was treated with nilotinib from 
week 12 onwards) to increase the power of these proof-
of-concept analyses. The clinical data, which are more 
sensitive to placebo effects, were not pooled but analyzed 
as observed with the last observation carried forward. P 
values of <0.05 were considered statistically significant, 
and p values <0.1 and ≥0.05 were considered to represent 
a trend.
Results
Immunomodulation of synovial inflammation by nilotinib 
treatment
To assess the modulation of synovial inflammation by 
nilotinib, synovial biopsies were obtained before and 
after treatment in pSpA patients with knee or ankle 
arthritis. Since the number of snap-frozen biopsies which 
passed quality control for immunohistological analy-
sis was small (n = 3 in the nilotinib group and n = 4 in 
the placebo group) we only used descriptive analyses for 
this part of the analysis. As shown in Table 2, the num-
ber of infiltrating CD68+ and CD163+ macrophages, 
which are markers for synovial inflammation in SpA [29, 
30, 38], numerically decreased in both the lining layer 
and the synovial sublining upon nilotinib treatment. In 
contrast, there was no consistent modulation of synovial 
macrophage numbers between baseline and week 12 of 
placebo treatment. Nilotinib treatment also decreased 
the number of c-Kit  +  synovial mast cells, while there 
was a numerical increase after placebo treatment. This 
was confirmed by qPCR analysis of mRNA expression, as 
c-Kit expression showed a significant decrease upon nilo-
tinib treatment but augmented upon placebo treatment 
over 12  weeks (p  =  0.037) (Fig.  1a). Additionally, nilo-
tinib treatment induced a decrease of the synovial mRNA 
expression of the pro-inflammatory cytokines IL-6 
(p = 0.024) and IL-23 (p = 0.024) compared to placebo, 
but not of IL-8 (p = 0.378) and TNF (p = 0.500) (Fig. 1b–
e). Expression levels of IL-17A and IL-17F were too low 
(even in the baseline biopsies) to allow reliable detection.
Modulation of systemic inflammation by nilotinib 
treatment in pSpA
As the tissue analysis indicated that nilotinib down-reg-
ulates synovial inflammation, we next examined whether 
systemic biomarkers of inflammation are also modu-
lated by nilotinib in pSpA (Fig. 2). CRP remained stable 
in the placebo group but decreased significantly from 9.2 
(IQR 1.7–33.1) to 5.2 (IQR 1.7–25.1) mg/l (p  =  0.024) 
upon 12 weeks of nilotinib treatment. This was particu-
larly marked in patients with high levels at baseline. CRP 
levels decreased even further after 24 weeks of nilotinib 
treatment to 4.0 (IQR 0.4–25.5) mg/l (p  =  0.031 com-
pared to baseline). The effect on ESR (p = 0.141) was less 
clear. Calprotectin showed a trend towards improvement 
after 12 weeks treatment with nilotinib decreasing from 
359.9 (IQR 183.3–484.9) to 287.9 (IQR 116.7–457.1) ng/
ml (p =  0.055), but stayed stable in the placebo group. 
MMP-3 also mainly decreased in patients with high lev-
els at baseline, but overall the median showed a slight 
increase after 12 weeks of nilotinib from 28.5 (IQR 11.6–
104.8) to 29.3 (IQR 12.3–46.0) ng/ml (p = 0.034).
Improvement of clinical symptoms after nilotinib 
treatment in pSpA
In line with the synovial tissue and serum biomarker 
analyses nilotinib treatment induced a significant reduc-
tion in patient’s global assessment at week 12 (p = 0.031) 
as well as after an additional 12 weeks of open label treat-
ment with nilotinib (p = 0.031) (Fig. 3a). Moreover, the 
placebo treated patients did not show any changes in 
patient’s global assessment during the first phase of the 
study but showed significant improvement after entering 
the open label phase with nilotinib treatment (p = 0.012) 
(Fig.  3a). The physician’s global assessment showed a 
Table 2 Immunomodulatory effect of nilotinib versus pla-
cebo treatment on synovial histopathology
Values are the median (IQR) assessed on a semiquantitative scale
Marker Nilotinib Placebo
Week 0 Week 12 Week 0 Week 12
CD68 lining 1.7 (1.7–3.0) 0.3 (0.0–2.0) 2.8 (1.2–3.0) 2.3 (1.7–3.0)
CD68 sublining 2.0 (1.3–2.3) 0.0 (0.0–1.3) 2.0 (1.0–3.0) 1.7 (1.3–2.0)
CD163 lining 2.7 (2.0–2.7) 0.7 (0.0–2.0) 2.8 (0.7–3.0) 2.7 (2.7–2.7)
CD163 sublining 2.3 (2.3–2.7) 1.3 (0.3–2.0) 2.3 (1.4–3.0) 2.3 (2.3–2.3)
c-Kit 1.0 (0.3–2.3) 0.0 (0.0–0.7) 0.0 (0.0–0.8) 1.3 (0.3–2.3)
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trend towards improvement at week 12 (p = 0.063) and 
improved significantly at week 24 (p =  0.031) (Fig.  3b). 
The SJC66 and TJC68 decreased numerically between 
week 0 and 12 of nilotinib but not placebo treatment 
and decreased further at week 24, which was signifi-
cant for the SJC66 (p =  0.049). After entering the open 
label phase with nilotinib the originally placebo treated 
patients also showed significant improvement in SJC66 
(p = 0.031) (Fig. 3c, d). The ASDAS, a composite meas-
ure originally developed for axSpA but which was also 
shown to be useful in pSpA [39], improved after 12 weeks 
of nilotinib treatment (p = 0.031), which was not the case 
for placebo (p = 0.371) (Fig. 3e). ASDAS clinically impor-
tant improvement was reached by 40.0 % of the nilotinib 
group at week 12 (Fig. 3f ) and by 53.8 % of the total study 
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Fig. 1 Synovial tissue mRNA expression in peripheral spondyloarthritis. Effect of nilotinib and placebo treatment on in vivo synovial tissue mRNA 
expression in peripheral spondyloarthritis as assessed by quantitative polymerase chain reaction. The panel represents the transcription of c-Kit, 
interleukin-6 (IL-6), IL-8, tumor necrosis factor (TNF), and IL-23 before and after treatment with nilotinib (a–e) or placebo (f–j). The lines connect the 
data points for each patient between weeks (week) 0 and 12
CRP Nilotinib
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Fig. 2 Serum biomarkers in peripheral spondyloarthritis. Effect of nilotinib and placebo on serum biomarkers of patients with peripheral spon-
dyloarthritis. The panel represents the C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), calprotectin and matrix metalloproteinase-3 
(MMP-3) levels before (week 0) and after treatment (week 12) with nilotinib (a–d) or placebo (e–h). The lines connect the data points for each 
patient. *P value <0.05
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Lack of effect of nilotinib treatment in axSpA
Although the rational to study nilotinib treatment in 
SpA was based on synovial tissue findings in pSpA, we 
also explored the effect of nilotinib in axSpA since the 
published open label trial with imatinib also showed 
improvement in axial symptoms [23]. In contrast with 
pSpA, however, serum CRP (baseline 4.2 (IQR 2.9–8.0) 
mg/l versus week 12 7.8 (IQR 2.4–25.5) mg/l, p = 0.054) 
as well as the other tested systemic biomarkers of inflam-
mation did not show a reduction but even an increase 
after nilotinib treatment (Fig.  4). More importantly, 
the clinical parameters did not improve upon nilotinib 
treatment, while the placebo response was unexpect-
edly high for this patient group (Fig.  5). Patient’s and 
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Fig. 3 Clinical disease activity in peripheral spondyloarthritis. Changes in clinical disease activity parameters during treatment with nilotinib or 
placebo from week 0 until week 12, and during the open label extension phase with nilotinib from week 12 until week 24 in patients with periph-
eral spondyloarthritis. The panel represents the median (interquartile range) in patient’s global assessment of disease activity (a), physician’s global 
assessment of disease activity (b), swollen joint count (c), tender joint count (d), ankylosing spondylitis disease activity score (ASDAS) (e), and the 
percentage of patients achieving ASDAS clinically important improvement (f). *P value <0.05 compared to baseline
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physician’s global assessment were unchanged at week 12 
for the nilotinib arm but, surprisingly, was significantly 
decreased in the placebo group (from 70 (IQR 60–86) 
to 47 (IQR 34–96) mm, p  =  0.046, and from 55 (IQR 
50–60) to 45 (IQR 21–54) mm, p = 0.010, respectively). 
BASDAI (from 5.9 (IQR 4.2–6.9) to 7.4 (IQR 6.3–8.1), 
p  =  0.039) and ASDAS (from 3.2 (IQR 2.6–3.6) to 3.9 
(IQR 3.3–5.0), p  =  0.020) were even increased at week 
12 in the nilotinib treated patients. ASDAS clinically 
important improvement at week 12 was reached more 
often in the placebo group (33.3 %) than in the nilotinib 
group (0 %) (p = 0.072), with a similar pattern for BAS-
DAI50 response (22.2 versus 0 % respectively, p = 0.156). 
This was even more striking at week 24 in which ASDAS 
clinically important improvement was reached in 44.4 % 
of the placebo treated patients compared to 0  % in the 
nilotinib group (p = 0.031), with again a similar pattern 
for the BASDAI50 response (44.4 versus 12.5  % respec-
tively, p = 0.149). Collectively, these data indicate a lack 
of effect of nilotinib on axSpA.
Safety analysis
Although the present study is too small in size and dura-
tion to come to stringent safety conclusions, there were 
no unexpected safety signals in comparison with already 
available large scale data in CML [24, 25]. The overall 
number of adverse events (AEs) was high in both the 
nilotinib and placebo group (Table  3). The most com-
mon AEs were headache, dermatologic conditions (rash 
or acne), and gastrointestinal complaints (stomach ache 
or nausea). In contrast to the CML trials, haematological 
and biochemical AEs occurred rarely (anemia, throm-
bocytopenia, hypomagnesemia, and lipase elevation 
occurred in one patient each). Significant prolongation 
of the QT-interval on the electrocardiogram did not 
occur. All AEs were transient but dose reduction (from 
400 mg twice daily to 400 mg once daily) was needed in 
seven patients (mostly temporarily), after which the AEs 
resolved. One patient developed an acute cholecystitis at 
week 21 for which he was hospitalized; this was consid-
ered a serious adverse event unrelated to the study drug.
Discussion
We recently proposed that mast cells may contribute to 
SpA synovitis by indicating that the number of infiltrat-
ing mast cells was specifically increased in SpA versus 
RA synovitis, SpA synovial mast cells contained IL-17A 
as assessed by immunostaining, and ex vivo targeting of 
mast cells with imatinib reduced inflammation in syno-
vial biopsy cultures [13]. The present study supports 
the role of mast cells in synovial inflammation by dem-
onstrating histological, biological and clinical effects 
of nilotinib treatment in pSpA. Tyrosine kinase inhibi-
tors such as nilotinib and imatinib target c-Kit, which is 
crucial for the survival of mast cells. In agreement with 
previous ex  vivo studies demonstrating that imatinib 
induces apoptosis of synovial mast cells [22], in  vivo 
treatment with nilotinib induced a decrease in the num-
ber of synovial mast cells and in c-Kit mRNA expression 
in pSpA. This was associated with a decrease in infiltrat-
ing macrophages, synovial expression of pro-inflamma-
tory cytokines such as IL-6, systemic CRP levels, and 
CRP Nilotinib
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Fig. 4 Serum biomarkers in axial spondyloarthritis. Effect of nilotinib and placebo on serum biomarkers of patients with axial spondyloarthritis. 
The panel represents the C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), calprotectin and matrix metalloproteinase-3 (MMP-3) 
levels before (week 0) and after treatment (week 12) with nilotinib (a–d) or placebo (e–h). The lines connect the data points for each patient. *P 
value <0.05
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clinical disease activity parameters. Importantly, the 
immunomodulatory effect of nilotinib was consistent 
across biological and clinical measurements and was not 
observed in the placebo group. Together with the pub-
lished small open label study with imatinib [23], these 
data indicate that tyrosine kinase inhibitors targeting 
mast cells appear to be able to suppress inflammation in 
pSpA and thereby support the potential role of mast cells 
in SpA pathogenesis.
Due to the proof-of-concept design, this study has 
limitations which should be considered when interpret-
ing the data. Firstly, the number of pSpA patients in the 
double-blind phase was small, particularly in the syno-
vial evaluation as the quality of the synovial biopsies was 
insufficient in a number of patients. Therefore the data 
for the biological parameters were pooled (weeks 0–12 
of the originally nilotinib treated patients with weeks 
12–24 of the patients receiving placebo originally and 
BASDAI50 response
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Fig. 5 Clinical disease activity in axial spondyloarthritis. Changes in clinical disease activity parameters during treatment with nilotinib or placebo 
from week 0 until week 12, and during the open label extension phase with nilotinib from week 12 until week 24 in patients with axial spondyloar-
thritis. The panel represents the median (interquartile range) in patient’s global assessment of disease activity (a), physician’s global assessment of 
disease activity (b), bath ankylosing spondylitis disease activity index (BASDAI) (c), ankylosing spondylitis disease activity score (ASDAS) (d), and the 
percentage of patients achieving a BASDAI50 response (e), and ASDAS clinically important improvement (f). *P value <0.05 compared to baseline
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subsequently nilotinib). Secondly, the week 12 primary 
endpoint was perhaps too short. Indeed, both CRP and 
clinical parameters tended to decrease even further after 
an additional 12  weeks of treatment. Thirdly, the study 
did not allow to define mechanistically how nilotinib 
exerted its immunomodulatory effects. Even though 
our analysis suggested an effect on synovial IL-23 but 
not TNF expression, the number of good quality syno-
vial biopsies was too small to determine reliably which 
inflammatory pathways are or are not modulated by nilo-
tinib. For example, mRNA expression of key cytokines 
such as IL-17A and IL-17F was too low for reliable 
analysis. Furthermore, c-Kit is not only expressed on 
mast cells but on other immune cells as well, including 
innate lymphoid cells, which can express and produce 
pro-inflammatory mediators [40]. Moreover, nilotinib 
can also target other tyrosine kinases such as c-Fms 
and platelet derived growth factor receptor (PDGF-R). 
C-Fms is expressed on CD163+ macrophages, which 
are significantly increased in SpA synovitis [29, 41, 42], 
and PDGF-R is a key molecule on myofibroblasts, which 
were recently shown to be specifically increased in SpA 
versus RA synovitis [43]. Since targeting mast cells, 
innate lymphoid cells, CD163+ macrophages, as well as 
myofibroblasts all might be beneficial in pSpA, it remains 
unknown how nilotinib actually reduces synovial and 
systemic inflammation. Finally, the potency of nilotinib 
compared to other treatments for pSpA such as sulfasala-
zine [17] or TNF blockade [39] is unknown, as we did not 
include an active comparator group.
Strikingly, the biological and clinical effects observed in 
pSpA were completely absent in axSpA. This is in agree-
ment with the concept that peripheral and axSpA might 
be driven by slightly distinct cellular and molecular mecha-
nisms [44]. For example, the major cellular source of IL-17 
in pSpA are mast cells and to a lesser degree neutrophils 
[13], while in axSpA neutrophils and myeloperoxidase 
(MPO)+ cells are the major IL-17 expressing cells [45]. The 
discrepant response to nilotinib between pSpA and axSpA 
is also in line with previous data with sulfasalazine, which 
also targets mast cells [18, 19] and has proven clinical effi-
cacy in peripheral but not axial disease [17]. Taken together, 
the histopathology and the studies with sulfasalazine and 
nilotinib point towards partially distinct inflammatory 
pathways in peripheral versus axial disease. However when 
interpreting these data, it must be considered that it was 
not the intention of the current trial to compare the efficacy 
of nilotinib between pSpA and axSpA, but between nilo-
tinib and placebo in an exploratory fashion, hence pSpA 
and axSpA were not compared to each other. The effect of 
nilotinib on enthesitis, dactylitis and extra-articular mani-
festations (psoriasis, inflammatory bowel disease, uveitis) 
of SpA remains to be investigated.
A final observation was the pronounced placebo 
response in axSpA, which was unusually high compared 
to what is commonly reported [46–48]. Although we do 
not have a clear explanation for this finding, this observa-
tion indicates that open label trials in axSpA should be 
Table 3 AEs possibly related to  nilotinib, occurring 
in more than one patient and all SAEs
Values are the number (percentage) of patients. The SAE concerned one 
case of hospital admission following laparoscopic surgery because of acute 
cholecystitis. The placebo/nilotinib treated patients received placebo from week 
0 until week 12, and nilotinib from week 12 until week 24
AE adverse event; SAE serious adverse event
Nilotinib (n = 13) Placebo/nilotinib 
(n = 15)
Week 0–24 Week 0–12 Week 12–24
Number of patients 
with AEs
13 (100.0) 14 (93.3) 13 (86.7)
 Infections
  Common cold 5 (38.5) 4 (26.7) 4 (26.7)
  Gastroenteritis 4 (30.8) 2 (13.3) 1 (6.7)
  Sinusitis 2 (15.4) 0 (0.0) 0 (0.0)
 Dermatological
  Rash/acne 8 (61.5) 2 (13.3) 6 (40.0)
  Hair loss 3 (23.1) 2 (13.3) 2 (13.3)
  Mastopathy 2 (15.4) 0 (0.0) 1 (6.7)
 Gastrointestinal
  Stomach ache 5 (38.5) 3 (20.0) 1 (6.7)
  Nausea 5 (38.5) 3 (20.0) 6 (40.0)
  Anorexia 2 (15.4) 3 (20.0) 2 (13.3)
  Weight loss 2 (15.4) 1 (6.7) 1 (6.7)
  Constipation 3 (23.1) 1 (6.7) 0 (0.0)
 Cardiological
  Palpitations 1 (7.7) 0 (0.0) 2 (13.3)
 Musculoskeletal
  Myalgia 3 (23.1) 0 (0.0) 2 (13.3)
  Peripheral edema 2 (15.4) 1 (6.7) 0 (0.0)
  Flank pain 3 (23.1) 0 (0.0) 0 (0.0)
 Neurological
  Headache 5 (38.5) 1 (6.7) 2 (13.3)
 Ear/nose/throat
  Cough 0 (0.0) 0 (0.0) 2 (13.3)
 Psychological
  Depressive feelings 2 (15.4) 0 (0.0) 0 (0.0)
 Other
  General malaise 1 (7.7) 0 (0.0) 1 (6.7)
  Tiredness 3 (23.1) 1 (6.7) 2 (13.3)
  Hot flushes 1 (7.7) 0 (0.0) 2 (13.3)
  Sicca 0 (0.0) 1 (6.7) 2 (13.3)
Number of patients 
with SAEs
1 (7.7) 0 (0.0) 0 (0.0)
 Hospital admission 1 (7.7) 0 (0.0) 0 (0.0)
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interpreted with caution and pleas for a double-blind pla-
cebo-controlled arm not only in large phase III trials but 
also in proof-of-concept trials.
Conclusions
This proof-of-concept study supports the concept that 
mast cells can contribute to synovial inflammation in 
SpA and that tyrosine kinase inhibition targeting these 
cells has a biological and clinical immunomodulatory 
effect in pSpA. A similar response was not observed in 
axSpA in this small exploratory trial. These results sup-
port further clinical evaluation of nilotinib in larger clini-
cal trials in pSpA as well as evaluation of other drugs 
targeting mast cells in SpA.
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